Bisphosphonates for osteoporosis

Stuart Ralston

doi:10.1007/978-3-319-12406-3_12

Bisphosphonates for osteoporosis

Stuart Ralston^*

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract / Description of output

Bisphosphonates are among the most widely used medicines for the treatment of bone diseases. They are generally well tolerated, serious adverse events are rare and the risk-benefit risk profile in osteoporotic patients is overwhelmingly favourable in most better option.

Original language	English
Title of host publication	Medicines for Women
Publisher	Springer
Pages	345-371
Number of pages	27
ISBN (Print)	9783319124063, 9783319124056
DOIs	https://doi.org/10.1007/978-3-319-12406-3_12
Publication status	Published - 18 Dec 2014

Access to Document

10.1007/978-3-319-12406-3_12

Cite this

@inbook{2c7428b2ada04d7fb9dd71946b8d8d62,

title = "Bisphosphonates for osteoporosis",

abstract = "Bisphosphonates are among the most widely used medicines for the treatment of bone diseases. They are generally well tolerated, serious adverse events are rare and the risk-benefit risk profile in osteoporotic patients is overwhelmingly favourable in most better option.",

author = "Stuart Ralston",

year = "2014",

month = dec,

day = "18",

doi = "10.1007/978-3-319-12406-3_12",

language = "English",

isbn = "9783319124063",

pages = "345--371",

booktitle = "Medicines for Women",

publisher = "Springer",

}

TY - CHAP

T1 - Bisphosphonates for osteoporosis

AU - Ralston, Stuart

PY - 2014/12/18

Y1 - 2014/12/18

N2 - Bisphosphonates are among the most widely used medicines for the treatment of bone diseases. They are generally well tolerated, serious adverse events are rare and the risk-benefit risk profile in osteoporotic patients is overwhelmingly favourable in most better option.

AB - Bisphosphonates are among the most widely used medicines for the treatment of bone diseases. They are generally well tolerated, serious adverse events are rare and the risk-benefit risk profile in osteoporotic patients is overwhelmingly favourable in most better option.

UR - http://www.scopus.com/inward/record.url?scp=84943400725&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-12406-3_12

DO - 10.1007/978-3-319-12406-3_12

M3 - Chapter

AN - SCOPUS:84943400725

SN - 9783319124063

SN - 9783319124056

SP - 345

EP - 371

BT - Medicines for Women

PB - Springer

ER -

Bisphosphonates for osteoporosis

Abstract / Description of output

Access to Document

Other files and links

Fingerprint

Cite this